A Single-Center, Randomized, 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Cannabidiol (Primary) ; Cannabidiol/tetrahydrocannabivarin-9 (Primary) ; Nabiximols; Nabiximols
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors PhytoTech Therapeutics
- 01 Oct 2018 Results published in the Clinical Pharmacology in Drug Development
- 30 Jun 2017 New trial record